Cargando…
CD-NP: A Novel Engineered Dual Guanylyl Cyclase Activator with Anti-Fibrotic Actions in the Heart
Natriuretic peptides (NPs) are cardioprotective through the activation of guanylyl cyclase (GC) receptors A and B. CD-NP, also known as cenderitide, is a novel engineered NP that was designed to uniquely serve as a first-in-class dual GC receptor agonist. Recognizing the aldosterone suppressing acti...
Autores principales: | Martin, Fernando L., Sangaralingham, S. Jeson, Huntley, Brenda K., McKie, Paul M., Ichiki, Tomoko, Chen, Horng H., Korinek, Josef, Harders, Gerald E., Burnett, John C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525541/ https://www.ncbi.nlm.nih.gov/pubmed/23272242 http://dx.doi.org/10.1371/journal.pone.0052422 |
Ejemplares similares
-
Cenderitide, a novel dual GC-A and GC-B receptor activator, is a potent chronic cardiorenal fibroinhibiting peptide which suppresses aldosterone and reduces proteinuria in models of ardiorenal fibrosis
por: Martin, Fernando L, et al.
Publicado: (2011) -
A novel designer natriuretic peptide CD-NP suppresses TGF-beta 1 induced collagen Type I production in human cardiac fibroblasts
por: Ichiki, Tomoko, et al.
Publicado: (2009) -
MANP: a novel particulate guanylyl cyclase A receptor/cGMP activator for resistant hypertension: preliminary first in human clinical trial results
por: Burnett, John C, et al.
Publicado: (2015) -
M-atrial natriuretic peptide and nitroglycerin in experimental acute hypertensive heart failure: differential actions of two cGMP activating therapeutics
por: McKie, Paul M, et al.
Publicado: (2013) -
M‐Atrial Natriuretic Peptide and Nitroglycerin in a Canine Model of Experimental Acute Hypertensive Heart Failure: Differential Actions of 2 cGMP Activating Therapeutics
por: McKie, Paul M., et al.
Publicado: (2014)